FDA Should Play Role In Rx Cost Control, Ex-HHS Assistant Sec. Slater Says
Executive Summary
FDA's mission should be expanded to include a role in controlling the cost of prescription drugs in the U.S., former HHS Assistant Secretary for Health Eve Slater maintains in a Jan. 20 New England Journal of Medicine editorial
You may also be interested in...
FDA Bar Coding Final Rule Sets Two-Year Implementation Timeline
FDA's pharmaceutical bar coding final rule has a shorter implementation timeline than the agency previously proposed
Outcomes Research May Be “Next Frontier” In Drug Development Science
Pharmaceutical outcomes research is the "next frontier" for drug development science, FDA Office of Pharmacoepidemiology & Statistical Science Director Paul Seligman, MD, said at a pharmaceutical outcomes research workshop in Tucson, Ariz. Jan. 23
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011